• Sygnature Discovery Appoints Dr Charles Woler as Chairman 1/14/2022
• New CFO Jordison Steps up at Sygnature Discovery 12/1/2021
• Sygnature Discovery Expands into Early CMC Development 6/17/2021
• Sygnature Discovery Appoints Dr. David Lustig to Spearhead US Expansion 5/7/2021
• Sygnature Discovery Expands US Presence with Office in Bay Area Biotech Hub 4/28/2021
• Sygnature Discovery Creates 2nd Integrated Drug Discovery Site At Alderley Park 2/19/2021
• Sygnature Discovery Invests ￡3m to Expand High-throughput Screening and Translational Onco... 12/17/2020
• Sygnature Discovery Expands DMPK Capabilities with Acquisition of XenoGesis 9/25/2020
• Sygnature Discovery and RenaSci Strengthen Drug Abuse Leadership with Appointment of Dr An... 9/10/2020
• Sygnature Discovery Boosts Senior Management Team with Appointment of Dr Paul Overton 6/24/2020
• Sygnature Expands Capabilities with Acquisition of Alderley Oncology 6/5/2020
• Sygnature Discovery provides state-of-the-art liquid handling machine to UK Government’s C... 4/16/2020
• Sygnature Discovery Strengthens DMPK Team 1/16/2020
• RenaSci Bolsters Kidney Disease and Fibrosis Capabilities with Senior Appointment 1/9/2020
• Sygnature Discovery Announces Collaboration with Software Firm SilcsBio 4/18/2019
• Sygnature: Senior Appointments Enhance Sygnature Discovery’s DMPK Capabilities 3/22/2019
• Sygnature Discovery Starts 2019 with Two Senior Appointments 2/18/2019
• Sygnature Discovery Establishes US Office in Cambridge, MA 11/28/2018
• Sygnature Discovery Announces Multi-target Drug Discovery Deal With Sitryx Therapeutics 11/9/2018